E2F1 and malignant colon neoplasm: Increased evidences have determined that aberrant activation of E2F1 is closely associated with a poor clinical outcome in various human cancers [28, 29], and it was shown that E2F1 played a positive role in colon cancer metastasis and drug resistance [30].